Domagrozumab

Domagrozumab (PF-06252616) (INN) is a humanized monoclonal antibody designed for the treatment of Duchenne muscular dystrophy.[1][2]

Domagrozumab
Monoclonal antibody
Type	Whole antibody
Source	Humanized (from mouse)
Target	GDF-8
Clinical data
Other names	PF-06252616
ATC code	none
Identifiers
CAS Number	1629605-31-7
ChemSpider	none
UNII	516MD5WQ24
KEGG	D11047
Chemical and physical data
Formula	C₆₃₆₆H₉₈₂₆N₁₆₉₀O₂₀₀₈S₄₆
Molar mass	143639.22 g·mol⁻¹

This drug was developed by Pfizer.

References

Statement On A Nonproprietary Name Adopted By The USAN Council - Domagrozumab, American Medical Association.
World Health Organization (2015). "International Nonproprietary Names for Pharmaceutical Substances (INN). Proposed INN: List 114" (PDF). WHO Drug Information. 29 (4).

This article is issued from Wikipedia. The text is licensed under Creative Commons - Attribution - Sharealike. Additional terms may apply for the media files.